291 related articles for article (PubMed ID: 22002336)
1. Renal responses to three types of renin-angiotensin system blockers in patients with diabetes mellitus on a high-salt diet: a need for higher doses in diabetic patients?
Hollenberg NK; Fisher ND; Nussberger J; Moukarbel GV; Barkoudah E; Danser AH
J Hypertens; 2011 Dec; 29(12):2454-61. PubMed ID: 22002336
[TBL] [Abstract][Full Text] [Related]
2. Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin-converting enzyme inhibitor, or an angiotensin receptor blocker.
O'Brien E; Barton J; Nussberger J; Mulcahy D; Jensen C; Dicker P; Stanton A
Hypertension; 2007 Feb; 49(2):276-84. PubMed ID: 17159081
[TBL] [Abstract][Full Text] [Related]
3. Effects of dual blockade of the renin angiotensin system in hypertensive type 2 diabetic patients with nephropathy.
Matos JP; de Lourdes Rodrigues M; Ismerim VL; Boasquevisque EM; Genelhu V; Francischetti EA
Clin Nephrol; 2005 Sep; 64(3):180-9. PubMed ID: 16175942
[TBL] [Abstract][Full Text] [Related]
4. Beneficial cardiac effects of the renin inhibitor aliskiren in spontaneously hypertensive rats.
van Esch JH; Moltzer E; van Veghel R; Garrelds IM; Leijten F; Bouhuizen AM; Danser AH
J Hypertens; 2010 Oct; 28(10):2145-55. PubMed ID: 20625318
[TBL] [Abstract][Full Text] [Related]
5. Direct inhibition of renin as a cardiovascular pharmacotherapy: focus on aliskiren.
Sepehrdad R; Frishman WH; Stier CT; Sica DA
Cardiol Rev; 2007; 15(5):242-56. PubMed ID: 17700383
[TBL] [Abstract][Full Text] [Related]
6. Renin inhibition by aliskiren prevents atherosclerosis progression: comparison with irbesartan, atenolol, and amlodipine.
Nussberger J; Aubert JF; Bouzourene K; Pellegrin M; Hayoz D; Mazzolai L
Hypertension; 2008 May; 51(5):1306-11. PubMed ID: 18391092
[TBL] [Abstract][Full Text] [Related]
7. Comparative efficacy and safety of aliskiren and irbesartan in patients with hypertension and metabolic syndrome.
Krone W; Hanefeld M; Meyer HF; Jung T; Bartlett M; Yeh CM; Rajman I; Prescott MF; Dole WP
J Hum Hypertens; 2011 Mar; 25(3):186-95. PubMed ID: 20376075
[TBL] [Abstract][Full Text] [Related]
8. Blockade of the renin-angiotensin-aldosterone system: a key therapeutic strategy to reduce renal and cardiovascular events in patients with diabetes.
Burnier M; Zanchi A
J Hypertens; 2006 Jan; 24(1):11-25. PubMed ID: 16331093
[TBL] [Abstract][Full Text] [Related]
9. Renal effects of aliskiren compared with and in combination with irbesartan in patients with type 2 diabetes, hypertension, and albuminuria.
Persson F; Rossing P; Reinhard H; Juhl T; Stehouwer CD; Schalkwijk C; Danser AH; Boomsma F; Frandsen E; Parving HH
Diabetes Care; 2009 Oct; 32(10):1873-9. PubMed ID: 19587362
[TBL] [Abstract][Full Text] [Related]
10. Renin angiotensin system blockade reduces urinary levels of soluble urokinase plasminogen activator receptor (suPAR) in patients with type 2 diabetes.
Persson F; Theilade S; Eugen-Olsen J; Rossing P; Parving HH
J Diabetes Complications; 2016; 30(8):1440-1442. PubMed ID: 27475262
[TBL] [Abstract][Full Text] [Related]
11. Aliskiren and valsartan combination therapy for the management of hypertension.
Epstein BJ
Vasc Health Risk Manag; 2010 Sep; 6():711-22. PubMed ID: 20859542
[TBL] [Abstract][Full Text] [Related]
12. Effect of dual blockade of the renin-angiotensin system on the progression of type 2 diabetic nephropathy: a randomized trial.
Fernandez Juarez G; Luño J; Barrio V; de Vinuesa SG; Praga M; Goicoechea M; Cachofeiro V; Nieto J; Fernández Vega F; Tato A; Gutierrez E;
Am J Kidney Dis; 2013 Feb; 61(2):211-8. PubMed ID: 22939518
[TBL] [Abstract][Full Text] [Related]
13. Hemodynamic and hormonal changes to dual renin-angiotensin system inhibition in experimental hypertension.
Moniwa N; Varagic J; Ahmad S; VonCannon JL; Simington SW; Wang H; Groban L; Brosnihan KB; Nagata S; Kato J; Kitamura K; Gomez RA; Lopez ML; Ferrario CM
Hypertension; 2013 Feb; 61(2):417-24. PubMed ID: 23232645
[TBL] [Abstract][Full Text] [Related]
14. Urinary renin and angiotensinogen in type 2 diabetes: added value beyond urinary albumin?
Persson F; Lu X; Rossing P; Garrelds IM; Danser AH; Parving HH
J Hypertens; 2013 Aug; 31(8):1646-52. PubMed ID: 23743807
[TBL] [Abstract][Full Text] [Related]
15. AT1 antagonism and renin inhibition in mice: pivotal role of targeting angiotensin II in chronic kidney disease.
Fraune C; Lange S; Krebs C; Hölzel A; Baucke J; Divac N; Schwedhelm E; Streichert T; Velden J; Garrelds IM; Danser AH; Frenay AR; van Goor H; Jankowski V; Stahl R; Nguyen G; Wenzel UO
Am J Physiol Renal Physiol; 2012 Oct; 303(7):F1037-48. PubMed ID: 22791343
[TBL] [Abstract][Full Text] [Related]
16. Rational of the use of aliskiren in hypertension and beyond.
Westermann D; Savvatis K; Schultheiss HP; Tschöpe C
Minerva Cardioangiol; 2009 Dec; 57(6):761-72. PubMed ID: 20019651
[TBL] [Abstract][Full Text] [Related]
17. Aliskiren: a new inhibitor of renin-angiotensin aldosterone system activity.
Dalla Vestra M; Simioni N; Masiero A
Minerva Endocrinol; 2009 Dec; 34(4):333-8. PubMed ID: 20046162
[TBL] [Abstract][Full Text] [Related]
18. The role of angiotensin II antagonism in type 2 diabetes mellitus: a review of renoprotection studies.
Zanella MT; Ribeiro AB
Clin Ther; 2002 Jul; 24(7):1019-34. PubMed ID: 12182249
[TBL] [Abstract][Full Text] [Related]
19. An update of irbesartan and renin-angiotensin system blockade in diabetic nephropathy.
García-Donaire JA; Segura J; Ruilope LM
Expert Opin Pharmacother; 2005 Aug; 6(9):1587-96. PubMed ID: 16086646
[TBL] [Abstract][Full Text] [Related]
20. Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design.
Parving HH; Brenner BM; McMurray JJ; de Zeeuw D; Haffner SM; Solomon SD; Chaturvedi N; Ghadanfar M; Weissbach N; Xiang Z; Armbrecht J; Pfeffer MA
Nephrol Dial Transplant; 2009 May; 24(5):1663-71. PubMed ID: 19145003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
